QuidelOrtho sees Q1 revenue $615M-$620M, consensus $679.59M

The company currently expects preliminary unaudited revenue, as reported, of $615M-$620M for the first quarter of 2026. This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down by approximately 30% compared to the first quarter of 20251, along with slower China distributor sales that the company believes is related to the proposed China National Health Security Administration reimbursement rate reductions. Additionally, certain EMEA orders were delayed by the Middle East conflict, negatively impacting first quarter revenue. “Despite macroeconomic challenges and a softer first quarter respiratory season, QuidelOrtho (QDEL) is taking decisive cost actions to drive full-year 2026 performance,” said Brian Blaser, President and CEO, QuidelOrtho. “Our core businessrepresenting more than 70% of total revenueremains strong, providing a solid foundation amid near-term volatility. We remain focused on operational execution, margin expansion, cash flow improvement, and advancing our innovation pipeline to support durable long-term growth.”